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Abstract
Background: So	far,	there	has	been	no	tool	to	estimate	activity	at	diagnosis	and	pre‐
dict	all‐cause	mortality	in	patients	with	ANCA‐associated	vasculitis	(AAV).	Hence,	we	
determined	the	initial	predictors	of	them	in	patients	with	AAV.
Methods: We	 retrospectively	 reviewed	 the	medical	 records	 of	 182	 patients	 with	
AAV.	Severe	AAV	was	defined	as	Birmingham	Vasculitis	Activity	Score	(BVAS)	≥	16.	
The	cutoffs	were	extrapolated	by	the	receiver	operator	characteristic	(ROC)	curve.	
The	odds	ratio	(OR)	and	the	relative	risk	(RR)	were	assessed	using	the	multivariable	
logistic	regression	analysis	and	the	chi‐square	test,	respectively.
Results: In	the	comparison	analysis,	patients	with	severe	AAV	exhibited	the	higher	
neutrophil	and	platelet	counts,	creatinine,	erythrocyte	sedimentation	rate	and	C‐re‐
active	protein,	and	the	lower	lymphocyte	count,	hemoglobin,	and	serum	albumin	than	
those	without.	In	the	multivariable	logistic	regression	analysis,	creatinine	≥	0.9	mg/dL	
(OR	2.264),	lymphocyte	count	≤	1430.0/mm3	(OR	1.856),	and	hemoglobin	≤	10.8	g/
dL	(OR	2.085)	were	associated	with	severe	AAV.	We	developed	a	new	equation	of	a	
multivariable	index	for	AAV	(MVIA)	=	0.6	×	(Lymphocyte	count	≤	1430.0/mm3)	+	0.
7	×	(Hemoglobin	≤	10.8	g/dL)	+	0.8	×	(Creatinine	≥	0.9	mg/dL).	The	optimal	cutoff	of	
MVIA	for	severe	AAV	was	set	as	1.35.	Severe	AAV	was	identified	more	frequently	in	
patients	with	MVIA	at	diagnosis	≥1.35	than	those	without	(RR	4.432).	Patients	with	
MVIA	at	diagnosis	≥1.35	exhibited	the	 lower	cumulative	patient	survival	 rate	than	
those without.
Conclusion: Multivariable	index	for	AAV	could	assess	the	cross‐sectional	activity	and	
predict	all‐cause	mortality	in	patients	with	AAV.
K E Y W O R D S
activity,	ANCA‐associated	vasculitis,	multivariable	index,	prognosis
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1  | INTRODUC TION
Antineutrophil	 cytoplasmic	 antibody	 (ANCA)‐associated	 vasculi‐
tis	 (AAV)	 is	 a	 group	 of	 three	 systemic	 vasculitides	 involving	 small	
vessels,	such	as	microscopic	polyangiitis	(MPA),	granulomatosis	with	
polyangiitis	(GPA),	and	eosinophilic	granulomatosis	with	polyangiitis	
(EGPA)	according	 to	 the	2012	Chapel	Hill	Consensus	Conferences	
Nomenclature	 of	 Vasculitis	 (the	 2012	 CHCC	 definitions).1 On the 
basis	 of	 small‐vessel	 necrotizing	 vasculitis,	 MPA	 mainly	 provokes	
necrotizing	glomerulonephritis	and	pulmonary	capillaritis	and	GPA	
often causes granuloma formation of the upper and lower respi‐
ratory	 tracts	 and	 occasionally	 necrotizing	 glomerulonephritis.	
Meanwhile,	EGPA	is	characterized	by	three	typical	allergic	compo‐
nents	including	asthma,	peripheral	eosinophilia,	and	eosinophil‐rich	
granuloma of the respiratory tracts.1,2
A	 natural	 history	 of	 AAV	 was	 previously	 reported.	 The	 first‐
year	and	the	second‐year	mortality	 rates	were	82%	and	90%,	and	
the main etiology of mortality was uremia as a result of rapidly 
progressive glomerulonephritis.3	 As	 various	 therapeutic	 regimens	
were	developed	and	widely	used,	 the	first‐year	mortality	 rate	was	
remarkably	 decreased	 to	 <10%‐20%.4,5	Nevertheless,	 any	 delayed	
initiation	of	induction	therapy	for	severe	AAV	potentially	causes	ir‐
reversible	organ	damages,	which	is	eventually	jeopardizing	the	qual‐
ity	of	life.	Therefore,	the	early	diagnosis	and	treatment	for	AAV	are	
required	and	the	proper	selection	of	therapeutic	regimens	should	be	
carefully chosen based on the stage of the disease and its severity. 
Furthermore,	the	first	treatment	should	be	targeted	for	induction	of	
remission.2
Birmingham	Vasculitis	Activity	Score	 (BVAS)	has	been	used	for	
assessing	the	activity	and	severity	of	AAV,	and	it	was	reportedly	as‐
sociated	with	the	poor	prognosis	of	AAV.6,7	Five‐factor	score	(FFS;	
2009)	was	also	used	to	predict	the	poor	prognosis.8	Besides	BVAS	
and	FFS	(2009),	several	other	indices	have	been	applied	to	Korean	
patients	with	AAV,	 in	 order	 to	 estimate	AAV	 activity	 at	 diagnosis	
and	predict	the	poor	prognosis.	However,	there	has	been	no	tool	to	
estimate	AAV	activity	at	diagnosis	and	predict	all‐cause	mortality	in	
patients	with	AAV,	and	thus,	there	has	been	a	great	need	for	a	new	
AAV‐specific	index	for	assessing	the	cross‐sectional	activity	at	diag‐
nosis	and	predicting	the	prognosis	during	follow‐up	in	patients	with	
AAV.	To	elucidate	these	issues,	in	this	study,	we	screened	variables	
at	diagnosis	which	were	associated	with	severe	AAV	and	determined	
the	initial	predictors	of	the	cross‐sectional	activity	at	diagnosis	and	
all‐cause	 mortality	 during	 follow‐up	 in	 immunosuppressive	 drug‐
naïve	patients	with	AAV.
2  | MATERIAL S AND METHODS
2.1 | Patients
We retrospectively screened the medical records of 209 patients 
with	AAV	and	reviewed	those	of	182	patients	with	AVV,	who	met	
the	conditions	as	follows:	(a)	the	first	classification	as	AAV	at	the	
Division	of	Rheumatology,	 the	Department	of	 Internal	Medicine,	
Yonsei	University	College	of	Medicine,	 Severance	Hospital	 from	
October	2000	 to	April	 2018;	 (b)	 the	 fulfillment	of	 the	American	
College	 of	 Rheumatology	 1990	 criteria	 for	 GPA	 and	 EGPA	 and	
then	the	reclassification	as	AAV	by	the	2007	European	Medicines	
Agency	algorithm	and	the	2012	CHCC	definitions1,9‐11;	(c)	the	fol‐
low‐up	duration	of	at	 least	three	months	or	greater;	 (d)	the	well‐
documented medical records precise enough to assess calculate 
BVAS	 and	 FFS	 (2009)6,8;	 (e)	 the	 presence	 of	 the	 results	 of	 peri‐
nuclear	(P)‐ANCA	and	cytoplasmic	(C)‐ANCA	or	myeloperoxidase	
(MPO)‐ANCA	and	proteinase	3	(PR3)‐ANCA	at	diagnosis12;	 (f)	no	
other medical conditions at diagnosis to confuse the classification 
of	AAV,	which	were	 identified	 by	 the	10th	 revised	 International	
Classification	of	Diseases	(ICD‐10)13;	and	(g)	no	history	of	immu‐
nosuppressive	 drugs	 prior	 to	 or	 at	 diagnosis	 of	 AAV,	which	was	
verified	 by	 the	 Korean	 Drug	 Utilisation	 Review	 (DUR)	 system.	
This	study	was	approved	by	the	Institutional	Review	Board	 (IRB)	
of	Severance	Hospital	(4‐2017‐0673),	and	the	patient's	written	in‐
formed	consent	was	waived	by	 the	approving	 IRB,	 as	 this	was	a	
retrospective study.
2.2 | Data at diagnosis of AAV
We	obtained	age	at	diagnosis	and	gender	in	patients	with	AAV.	We	
reviewed clinical manifestations and laboratory data at diagnosis 
and	then	calculated	BVAS	and	FFS	(2009).	We	collected	laboratory	
results	at	diagnosis,	such	as	white	blood	cell,	neutrophil,	lympho‐
cyte	and	platelet	counts,	hemoglobin,	prothrombin	time	(interna‐
tional	normalized	ratio,	INR),	fasting	glucose,	blood	urea	nitrogen,	
creatinine,	 total	 protein,	 serum	 albumin,	 alkaline	 phosphatase,	
aspartate	aminotransferase,	alanine	aminotransferase,	total	biliru‐
bin,	erythrocyte	sedimentation	rate	(ESR),	and	C‐reactive	protein	
(CRP).
2.3 | Data during follow‐up
We	defined	the	follow‐up	duration	as	the	period	from	diagnosis	to	
the	 last	 visit	 for	 patients	with	 remission	 and/or	 survived	patients,	
and we defined it as the period from diagnosis to death for deceased 
patients.	 Since	 chronic	 kidney	 disease,	 end‐stage	 renal	 disease,	
ischemic	 heart	 disease,	 congestive	 heart	 failure,	 interstitial	 lung	
disease,	and	cerebrovascular	disease	belong	 to	 items	of	BVAS,	we	
also counted the number of patients with diabetes mellitus and hy‐
pertension among comorbidities. We reviewed the administration 
of	 immunosuppressive	drugs	during	follow‐ups	such	as	glucocorti‐
coid,	cyclophosphamide,	azathioprine,	rituximab,	methotrexate,	my‐
cophenolate	mofetil,	and	tacrolimus.	Death	was	defined	as	all‐cause	
mortality.
2.4 | Severe AAV
We	stratified	patients	with	AAV	into	three	groups	based	on	the	ter‐
tile	of	BVAS	and	defined	the	lower	limit	of	the	highest	tertile	as	the	
cutoff	for	the	current	severe	AAV	(BVAS	at	diagnosis	≥16).
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2.5 | Statistical analyses
All	statistical	analyses	were	conducted	using	SPSS	software	(version	
23	for	Windows;	 IBM	Corp).	Continuous	variables	were	expressed	
as	a	median	(interquartile	range,	IQR),	and	categorical	variables	were	
expressed	as	number	and	the	percentage.	Significant	differences	in	
categorical	variables	between	the	two	groups	were	analyzed	using	
chi‐square	 and	Fisher's	 exact	 tests.	 Significant	differences	 in	 con‐
tinuous variables between the two groups were compared using the 
Mann‐Whitney	test.	The	optimal	cutoffs	of	 laboratory	variables	at	
diagnosis	for	severe	AAV	were	extrapolated	by	calculating	the	area	
under	 the	 receiver	operator	characteristic	 curve	 (AUROC)	and	se‐
lecting	the	point	to	maximize	the	sum	of	sensitivity	and	specificity.	
The	odds	ratio	(OR)	was	assessed	using	the	multivariable	logistic	re‐
gression analysis of variables with P	values	<.05	on	the	univariable	
logistic	regression	analysis.	The	relative	risk	(RR)	of	the	optimal	cut‐
off	was	analyzed	using	contingency	tables	and	the	chi‐square	test.	
Comparison of cumulative patient survival between the two groups 
was	analyzed	by	the	Kaplan‐Meier	survival	analysis.	In	this	study,	P 
values	less	than	0.05	were	considered	statistically	significant.
3  | RESULTS
3.1 | Baseline characteristics of patients with AAV
Demographic,	clinical,	and	laboratory	data	at	diagnosis	of	AAV	were	
described in Table 1. The most common clinical manifestation at 
diagnosis	 was	 renal	 involvement	 (58.2%),	 followed	 by	 pulmonary	
involvement	 (56.0%).	The	median	BVAS	and	FFS	 (2009)	at	diagno‐
sis	were	12.0	 (11.0)	and	1.0	 (1.0),	 respectively.	The	median	values	
of	 laboratory	 results	were	shown	 in	Table	1.	During	 the	 follow‐up	
of	 the	median	duration	of	39.5	 (72.0)	months,	36	patients	 (19.8%)	
had	diabetes	mellitus	and	76	patients	(41.8%)	had	hypertension.	The	
most	frequently	administered	 immunosuppressive	drug	was	gluco‐
corticoid	 (86.8%),	 followed	by	cyclophosphamide	 (41.8%)	and	aza‐
thioprine	(53.3%).	Fifteen	patients	(8.2%)	died	of	all	etiologies	during	
follow‐up	(Table	1).
3.2 | Comparison of laboratory variables at 
diagnosis between AAV patients with and without 
severe AAV
Sixty‐three	patients	had	BVAS	more	than	16	and	were	classified	as	se‐
vere	AAV.	There	were	no	differences	in	age	and	gender	between	the	
two groups. Because clinical manifestations at diagnosis were based 
on	all	 items	of	BVAS,	as	was	expected,	patients	with	BVAS	at	diag‐
nosis	≥16	exhibited	the	higher	frequencies	of	renal,	pulmonary,	gen‐
eral,	 cardiovascular,	 and	 gastrointestinal	 manifestations	 than	 those	
without.	Compared	with	non‐severe	AAV	patients,	patients	with	se‐
vere	AAV	had	the	increased	median	neutrophil	count,	platelet	count,	
blood	urea	nitrogen,	creatinine,	ESR,	and	CRP	than	those	without.	On	
the	other	hands,	patients	with	severe	AAV	exhibited	the	 lower	me‐
dian	 lymphocyte	count,	hemoglobin,	and	serum	albumin	than	those	
without	(Table	2).	As	there	was	collinearity	between	blood	urea	nitro‐
gen	and	creatinine,	we	excluded	it	in	the	following	analyses.
3.3 | Optimal cutoffs of laboratory variables for 
severe AAV at diagnosis
We obtained the optimal cutoffs of laboratory variables at diag‐
nosis	 for	 severe	 AAV,	 which	 were	 significant	 in	 the	 comparative	
analysis	 between	 patients	with	 and	without	 severe	AAV.	 The	 op‐
timal	cutoffs	of	variables	are	as	below:	neutrophil	count	≥	7570.0/
mm3;	 lymphocyte	 count	 ≤	 1430.0/mm3;	 hemoglobin	 ≤	 10.8	 g/dL;	
platelet	count	≥	352	500.0/mm3;	creatinine	≥	0.9	mg/dL;	serum	al‐
bumin	≤	3.5	g/dL;	ESR	≥	83.5	mm/h;	and	CRP	≥	20.0	mg/L	 (Table	
S1).	 Although	 platelet	 count	 exhibited	 no	 statistical	 significance	
(area	0.568,	95%	confidence	interval	(CI)	0.475,	0.661),	we	included	
platelet	count	≥	352	500.0/mm3	in	the	logistic	regression	analyses,	
because it significantly differed between patients with and without 
severe	AAV	in	the	comparison	analysis.
3.4 | Univariable and multivariable logistic 
regression analyses for severe AAV at diagnosis
Since	there	were	no	significant	differences	 in	age	at	diagnosis	and	
gender	 between	 the	 two	 groups,	 we	 did	 not	 include	 them	 in	 the	
univariable and multivariable logistic regression analyses. In the 
univariable logistic regression analysis of laboratory variables at 
diagnosis	for	severe	AAV,	all	 laboratory	variables	with	significance	
in the comparative analysis exhibited significant ORs: neutrophil 
count	 ≥	 7570.0/mm3	 (OR	 2.499);	 lymphocyte	 count	 ≤	 1430.0/
mm3	 (OR	 2.664);	 hemoglobin	 ≤	 10.8	 g/dL	 (OR	 4.348);	 platelet	
count	 ≥	 352	 500.0/mm3	 (OR	 2.325);	 creatinine	 ≥	 0.9	 mg/dL	 (OR	
3.536);	serum	albumin	≤	3.5	g/dL	(OR	2.770);	ESR	≥	83.5	mm/h	(OR	
3.051);	and	CRP	≥	20.0	mg/L	(OR	2.770;	Table	3).	In	the	multivariable	
logistic regression analysis of laboratory variables at diagnosis for 
severe	AAV,	only	creatinine	≥	0.9	mg/dL	was	significantly	associated	
with	severe	AAV	at	diagnosis	(OR	2.264,	95%	CI	1.107,	5.040).	In	ad‐
dition,	lymphocyte	count	≤	1430.0/mm3	and	hemoglobin	≤	10.8	g/
dL	also	tended	to	be	associated	with	severe	AAV	at	diagnosis	 (OR	
1.856,	95%	CI	0.906,	3.804	and	OR	2.085,	95%	CI	0.917,	4.737,	re‐
spectively;	Table	3).	We	derived	an	equation	of	a	multivariable	index	
for	AAV	(MVIA)	using	lymphocyte	count,	hemoglobin,	and	creatinine	
with P	value	<	.01	in	the	multivariable	logistic	regression	analysis.
3.5 | Equation of MVIA
We assigned a weight of a number close to an integer to each 
variable according to the slopes for independent variable with P 
value	<	.1	in	the	multivariable	logistic	regression	analysis:	B	=	0.6	for	
Lymphocyte	≤	1430.0/mm3,	B	=	0.7	for	Hemoglobin	≤	10.8	g/dL,	and	
B	=	0.8	for	Creatinine	≥	0.9	mg/dL	(Table	3).	And	we	developed	a	new	
equation	as	follows:	a	multivariable	index	for	AAV	(MVIA)	=	0.6	×	(L
ymphocyte	≤	1430.0/mm3:	yes	=	1	or	no	=	0)	+	0.7	×	(Hemoglobin	≤	
10.8	g/dL:	yes	=	1	or	no	=	0)	+	0.8	×	(Creatinine	≥0.9	mg/dL:	yes	=	1	
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or	no	=	0).	For	instance,	if	a	patient	had	lymphocyte	≤	1430.0/mm3,	
hemoglobin	 ≤	 10.8	 g/dL,	 and	 creatinine	 ≥	 0.9	mg/dL,	 that	 patient	
would	have	MVIA	of	2.1	(0.6	×	1	+	0.7	×	1	+	0.8	×	1).
3.6 | Optimal cutoff of MVIA for severe AAV
The	median	calculated	MVIA	was	0.8	with	IQR	of	1.5.	The	maximum	
and	minimum	MVIA	were	2.1	 and	0,	 respectively.	MVIA	was	posi‐
tively	correlated	with	BVAS	at	diagnosis	(r	=	0.370,	P	<	.001).	We	also	
obtained	the	optimal	cutoff	of	MVIA	for	severe	AAV	as	1.35	(sensitiv‐
ity	0.667	and	specificity	0.689)	using	the	AUROC	curve	(area	0.727,	
95%	CI	0.648,	0.805;	Figure	1A).	When	we	divided	patients	with	AAV	
into	the	two	groups	based	on	the	optimal	cutoff	of	MVIA	for	severe	
AAV,	79	patients	belonged	to	the	group	of	MVIA	at	diagnosis	≥1.35.	
The	cross‐sectional	severe	AAV	appeared	more	frequently	in	patients	
with	MVIA	at	diagnosis	≥1.35	than	those	without	(53.2%	vs	20.4%,	
P	<	.001).	In	addition,	patients	with	MVIA	at	diagnosis	≥1.35	exhib‐
ited	a	significantly	high	RR	for	severe	AAV	at	diagnosis,	compared	to	
those	without	(RR	4.432,	95%	CI	2.309,	8.507;	Figure	1B).
3.7 | Cumulative patient survival rate
We	investigated	the	cumulative	patient	survival	rate	during	follow‐
up	 between	 patients	 with	 and	 without	 MVIA	 at	 diagnosis	 ≥1.35.	
TA B L E  1  Characteristics	of	182	patients	with	AAV	at	diagnosis	
and	during	follow‐up
Variables Values
At	diagnosis
Demographic data at diagnosis
Age	(year	old) 58.5	(21.0)
Male	gender	(N,	[%]) 55	(30.2)
Variants	of	AAV
MPA 97	(53.3)
GPA 45	(24.7)
EGPA 40	(22.0)
ANCA	at	diagnosis	(N,	[%])
MPO‐ANCA	(or	P‐ANCA) 117	(64.3)
PR3‐ANCA	(or	C‐ANCA) 30	(16.5)
MPO‐ANCA	(or	P‐ANCA)	and	PR3‐
ANCA	(or	C‐ANCA)
9	(4.9)
ANCA	negativity 44	(24.2)
Clinical	manifestations	at	diagnosis	(N,	[%])
Renal 106	(58.2)
Pulmonary 102	(56.0)
General 80	(44.0)
Ear	Nose	Throat 68	(37.4)
Nervous	system 56	(30.8)
Cardiovascular 47	(25.8)
Cutaneous 41	(22.5)
Mucous membranes/eyes 12	(6.6)
Gastrointestinal 10	(5.5)
Vasculitis	activity	and	prognostic	factors	at	diagnosis
BVAS	or	BVAS	for	GPA 12.0	(11.0)
FFS	(2009) 1.0	(1.0)
Laboratory	results	at	diagnosis
White blood cell (/mm3) 9260.0	(6425.0)
Neutrophil	(/mm3) 6510.0	(6000.0)
Lymphocyte	(/mm3) 1480.0	(980.0)
Hemoglobin	(g/dL) 11.6	(3.7)
Platelet	(×1000/mm3) 307.5	(164.5)
Prothrombin	time	(INR) 1.0	(0.2)
Fasting	glucose	(mg/dL) 101.0	(34.0)
Blood	urea	nitrogen	(mg/dL) 17.4	(19.4)
Creatinine	(mg/dL) 1.0	(1.3)
Total	protein	(g/dL) 6.6	(1.3)
Serum	albumin	(g/dL) 3.6	(1.1)
Alkaline	phosphatase	(IU/L) 68.5	(37.3)
Aspartate	aminotransferase	(IU/L) 18.0	(8.0)
Alanine	aminotransferase	(IU/L) 15.0	(14.0)
Total	bilirubin	(mg/dL) 0.5	(0.2)
ESR	(mm/h) 57.5	(70.0)
(Continues)
Variables Values
CRP	(mg/L) 14.5	(60.2)
During	follow‐up
Follow‐up	duration	(mo) 39.5	(72.0)
Comorbidities	(N,	[%])
Diabetes mellitus 36	(19.8)
Hypertension 76	(41.8)
Immunosuppressive	drugs	(N,	[%])
Glucocorticoid 158	(86.8)
Cyclophosphamide 76	(41.8)
Azathioprine 97	(53.3)
Rituximab 19	(10.4)
Methotrexate 13	(7.1)
Mycophenolate mofetil 10	(5.5)
Tacrolimus 9	(4.9)
Prognosis	(N,	[%])
All‐cause	mortality 15	(8.2)
Note: Values	are	expressed	as	a	median	(interquartile	range	[IQR])	or	N	(%).
Abbreviations:	AAV,	antineutrophil	cytoplasmic	antibody	(ANCA)‐as‐
sociated	vasculitis;	ANCA,	antineutrophil	cytoplasmic	antibody;	BVAS,	
Birmingham	Vasculitis	Activity	Score;	C‐ANCA,	cytoplasmic	ANCA;	
CRP,	C‐reactive	protein;	EGPA,	eosinophilic	granulomatosis	with	poly‐
angiitis;	ESR,	erythrocyte	sedimentation	rate;	FFS,	five‐factor	score;	
GPA,	granulomatosis	with	polyangiitis;	MPA,	microscopic	polyangiitis;	
MPO,	myeloperoxidase;	P‐ANCA,	perinuclear	ANCA;	PR3,	proteinase	3;	
WBC,	white	blood	cell.
TA B L E  1   (Continued)
     |  5 of 8KIM et al.
Patients	with	MVIA	at	diagnosis	≥1.35	exhibited	the	lower	cumula‐
tive	patient	survival	rate	than	those	with	MVIA	<1.35	(P	=	.006).	We	
also	applied	the	Kaplan‐Meier	survival	analysis	to	all	laboratory	vari‐
ables having optimal cutoffs and found only hemoglobin at diagno‐
sis	≤10.8	g/dL	was	significantly	associated	with	all‐cause	mortality	in	
patients	with	AAV	(P	=	.006;	Figure	2).
4  | DISCUSSION
In	this	study,	we	derived	a	new	equation	of	MVIA	using	labora‐
tory	variables	significantly	associated	with	severe	AAV	at	diag‐
nosis	and	successfully	documented	that	MVIA	could	assess	the	
cross‐sectional	activity	and	severity	at	diagnosis	and	predict	all‐
cause	 mortality	 during	 follow‐up	 in	 immunosuppressive	 drug‐
naïve	patients	with	AAV.	First,	our	findings	suggest	that	patients	
with	severe	AAV	exhibited	the	higher	median	neutrophil	count,	
platelet	count,	creatinine,	ESR,	and	CRP,	and	showed	the	lower	
median	lymphocyte	count,	hemoglobin,	and	serum	albumin	than	
those	without.	Second,	we	obtained	the	optimal	cutoff	of	each	
variable with significance in the comparative analysis using the 
AUROC	curve.	Third,	in	the	univariable	and	multivariable	logistic	
regression	analysis,	we	found	that	lymphocyte	count	≤	1430.0/
mm3,	hemoglobin	≤	10.8	g/dL,	and	creatinine	≥	0.9	mg/dL	were	
meaningfully	 associated	 with	 the	 cross‐sectional	 severe	 AAV.	
Using	these	three	variables	at	diagnosis,	we	derived	a	new	equa‐
tion	of	MVIA.	The	optimal	cutoff	of	MVIA	for	severe	AAV	was	
identified	as	1.35.	Fourth,	 the	cross‐sectional	 severe	AAV	was	
identified	 more	 frequently	 in	 patients	 with	 MVIA	 at	 diagno‐
sis	≥1.35	 than	 those	without	 (RR	4.432,	95%	CI	2.309,	 8.507).	
Fifth,	in	the	survival	analysis,	MVIA	at	diagnosis	≥1.35	was	sig‐
nificantly	associated	with	all‐cause	mortality	during	follow‐up.
Among	variables	routinely	measured	at	each	visit	in	the	clinics,	
in	 the	 univariable	 analysis,	 eight	 variables	 were	 associated	with	
severe	AAV,	and	furthermore,	in	the	multivariable	analysis,	creat‐
inine	at	diagnosis	≥0.9	mg/dL	alone	was	statistically	highly	asso‐
ciated	with	severe	AAV.	In	addition,	lymphocyte	count	≤	1430.0/
mm3	 and	 hemoglobin	 ≤	 10.8	 g/dL	 also	 tended	 to	 be	 associated	
with	 severe	AAV	 at	 diagnosis.	We	 explored	 an	 index	with	more	
than	two	variables	including	lymphocyte	count	≤	1430.0/mm3,	he‐
moglobin	≤	10.8	g/dL,	and	creatinine	≥	0.9	mg/dL	to	offset	against	
the	high	variability	in	one	variable,	which	eventually	could	be	more	
stable	 and	 reliable.	 For	 these	 reasons,	 MVIA	 showed	 the	 high‐
est	area	 for	severe	AAV	 in	 the	multivariable	AUROC	curve	 (area	
0.678,	95%	CI	0.595,	0.761),	compared	with	other	eight	variables	
at	diagnosis	(Figure	S1).
Why	did	we	need	to	calculate	MVIA	at	diagnosis,	 in	additional	
to	BVAS	at	diagnosis?	We	wondered	whether	patients	with	AAV	in	
the present study received the proper induction and maintenance 
therapies	based	on	the	cross‐sectional	activity.2,14 When we divided 
patients	with	AAV	 into	the	two	groups	based	on	MVIA	at	diagno‐
sis	 ≥1.35,	 79	 patients	 belonged	 to	 the	 group	 of	MVIA	 at	 diagno‐
sis	 ≥1.35.	We	 compared	 the	 use	 of	 cyclophosphamide,	 rituximab,	
TA B L E  2   Comparison of laboratory variables at diagnosis 
between	AAV	patients	with	and	without	BVAS	at	diagnosis	≥16
Variables
Patients 
with BVAS at 
diagnosis ≥16 
(N = 63)
Patients with 
BVAS at di‐
agnosis < 16 
(N = 119) P value
Demographic data at diagnosis
Age	(year	old) 62.0	(23.0) 56.0	(21.0) .057
Male	gender	(N,	[%]) 16	(25.4) 39	(32.8) .303
Clinical	manifestations	at	diagnosis	(N,	[%])
Renal 55	(87.3) 51	(42.9) <.001
Pulmonary 42	(66.7) 60	(50.4) .036
General 39	(61.9) 41	(34.5) <.001
Ear	Nose	Throat 21	(33.3) 47	(39.5) .414
Nervous	system 23	(36.5) 33	(27.7) .222
Cardiovascular 28	(44.4) 19	(16.0) <.001
Cutaneous 16	(25.4) 25	(21.0) .500
Mucous membranes/
eyes
4	(6.3) 8	(6.7) .923
Gastrointestinal 7	(11.1) 3	(2.5) .016
Laboratory	results	at	diagnosis
White blood cell (/mm3) 10	470.0	
(7210.0)
9040.0 
(5600.0)
.097
Neutrophil	(/mm3) 7640.0	
(6000.0)
5440.0	
(5000.0)
.025
Lymphocyte	(/mm3) 1210.0	(780.0) 1580.0	
(980.0)
.033
Hemoglobin	(g/dL) 9.9	(3.2) 12.3	(3.1) <.001
Platelet	(×1000/mm3) 337.0	(256.5) 301.0	(143.5) .032
Prothrombin	time	(INR) 1.0	(0.2) 1.0	(0.2) .310
Fasting	glucose	(mg/dL) 100.0	(33.0) 101.0	(34.0) .896
Blood urea nitrogen 
(mg/dL)
24.6	(23.8) 15.2	(11.8) .002
Creatinine	(mg/dL) 1.4	(2.1) 1.2	(0.7) .010
Total	protein	(g/dL) 6.4	(1.2) 6.8	(1.1) .910
Serum	albumin	(g/dL) 3.3	(1.4) 3.8	(1.1) <.001
Alkaline	phosphatase	
(IU/L)
68.0	(40.0) 69.0	(35.0) .745
Aspartate	aminotrans‐
ferase	(IU/L)
17.0	(9.0) 18.0	(8.0) .468
Alanine	aminotrans‐
ferase	(IU/L)
14.0	(16.0) 17.0	(13.3) .751
Total	bilirubin	(mg/dL) 0.4	(0.3) 0.5	(0.2) .361
ESR	(mm/h) 69.0	(88.0) 49.0	(59.0) .005
CRP	(mg/L) 27.2	(90.0) 7.5	(41.7) .015
Note: Values	are	expressed	as	a	median	(interquartile	range	[IQR])	or	N	
(%).
Abbreviations:	AAV,	antineutrophil	cytoplasmic	antibody	(ANCA)‐as‐
sociated	vasculitis;	ANCA,	antineutrophil	cytoplasmic	antibody;	BVAS,	
Birmingham	Vasculitis	Activity	Score;	CRP,	C‐reactive	protein;	ESR,	
erythrocyte sedimentation rate.
aBecause	blood	urea	nitrogen	is	closely	related	to	creatinine,	we	in‐
cluded only creatinine in the analysis. 
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and	azathioprine	between	patients	with	MVIA	at	diagnosis	≥1.35	and	
those without. Cyclophosphamide was administered to patients with 
MVIA	at	diagnosis	≥1.35	more	frequently	than	those	without	(44.7%	
vs	 29.1%,	 P	 <	 .001).	 Rituximab	 was	 evenly	 administered	 to	 both	
groups. Because only one cycle of rituximab in the whole life can be 
covered	by	the	Korean	National	Health	Insurance,	rituximab	might	
be	administered	as	an	induction	therapeutic	regimen.	Azathioprine	
was	also	administered	to	patients	with	MVIA	at	diagnosis	≥1.35	more	
frequently	than	those	without	(64.6%	vs	44.7%,	P	<	.001).	If	we	had	
serially	noticed	the	severity	of	AAV,	more	aggressive	therapies	could	
have	been	applied	 to	patients	with	 the	high	 severity	of	AAV.	This	
further	highlights	our	study	 that	MVIA	at	diagnosis	could	be	used	
as	 a	 supplementary	 index	 for	 severe	AAV.	 In	 the	 clinical	 settings,	
BVAS	might	be	affected	by	subjective	complaints,	such	as	myalgia	
or	arthralgia,	and	it	needs	more	tests	including	echocardiography	in	
a	patient	 suspected	of	myocarditis.	However,	 since	MVIA	consists	
of	only	laboratory	variables,	which	are	routinely	measured	at	every	
visit,	it	is	more	convenient	to	evaluate	the	severity	of	AAV.	And	fur‐
thermore,	 if	 we	 develop	 an	 automatic	 calculator	 of	MVIA,	 severe	
AAV	based	on	BVAS	may	be	rapidly	and	promptly	assessed.
TA B L E  3  Logistic	regression	analyses	for	severe	AAV	at	diagnosis
Variables at diagnosis
Univariable Multivariable
OR 95% CI P value B OR 95% CI P value
Neutrophil	≥7570.0/mm3 2.499 1.334,	4.681 .004 0.332 1.394 0.627,	3.099 .416
Lymphocyte	≤	1430.0/mm3 2.664 1.418,	5.007 .002 0.619 1.856 0.906,	3.804 .091
Hemoglobin	≤	10.8	g/dL 4.348 2.272,	8.320 .001 0.735 2.085 0.917,	4.737 .079
Platelet	≥	352	500.0/mmy3 2.325 1.236,	4.374 .009 0.448 1.566 0.624,	3.931 .340
Creatinine	≥	0.9	mg/dL 3.536 1.805,	6.926 <.001 0.817 2.264 1.107,	5.040 .045
Serum	albumin	≤	3.5	g/dL 2.770 1.475,	5.202 .002 0035 1.036 0.457,	2.348 .933
ESR	≥	83.5	mm/h 3.051 1.578,	5.898 .001 0.507 1.660 0.682,	4.045 .264
CRP	≥	20.0	mg/L 2.770 1.475,	5.202 .002 0.023 1.023 0.427,	2.452 .960
Abbreviations:	AAV,	antineutrophil	cytoplasmic	antibody	(ANCA)‐associated	vasculitis;	ANCA,	antineutrophil	cytoplasmic	antibody;	CRP,	C‐reactive	
protein;	ESR,	erythrocyte	sedimentation	rate.
F I G U R E  1  Optimal	cutoff	of	MVIA	for	severe	AAV.	A,	The	optimal	cutoff	of	MVIA	at	diagnosis	for	severe	AAV	was	obtained	as	1.35	
(sensitivity	0.667	and	specificity	0.689).	B,	Patients	with	MVIA	at	diagnosis	≥1.35	exhibited	a	significantly	high	RR	for	severe	AAV	at	
diagnosis,	compared	to	those	without	(RR	4.432,	95%	CI	2.309,	8.507).	AAV,	antineutrophil	cytoplasm	antibody	(ANCA)‐associated	
vasculitis;	CI,	confidence	interval;	MVIA,	a	multivariable	index	for	AAV;	RR,	relative	risk
F I G U R E  2  All‐cause	mortality	rate.	
Patients	with	MVIA	at	diagnosis	≥1.35	
(P	=	.006)	and	hemoglobin	at	
diagnosis	≤10.8	g/dL	(P	=	.006)	were	
significantly	associated	with	all‐cause	
mortality	in	AAV	patients.	AAV,	
antineutrophil cytoplasm antibody 
(ANCA)‐associated	vasculitis;	MVIA,	a	
multivariable	index	for	AAV
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So	why	does	MVIA	at	diagnosis	 reflects	 severe	AAV	based	on	
BVAS	at	diagnosis?	We	guessed	that	MVIA	may	estimate	severe	AAV	
well	because	its	parameters	could	reflect	severe	AAV	(the	high	ac‐
tivity	of	AAV)	better	than	other	laboratory	values.	First,	lymphocyte	
count may also be affected by general health and stress or various 
autoimmune diseases and we previously proved the lower number 
of	 lymphocyte	 in	 severe	 AAV	 compared	 with	 non‐severe	 AAV.15 
Second,	 the	 reduced	 hemoglobin	 was	 reported	 to	 be	 one	 of	 sys‐
temic	complication	of	AAV.16	Third,	serum	creatinine	level	is	already	
included	in	BVAS	as	one	item,	and	thus,	it	is	naturally	accepted	that	
the	serum	level	of	creatinine	might	be	correlated	with	BVAS	well.6
We	 found	 that	MVIA	 at	 diagnosis	 ≥1.35	 was	 significantly	 as‐
sociated	 with	 all‐cause	 mortality.	 Although	 the	 poor	 prognosis	
includes	 various	 clinical	 situations	 such	 as	 relapse,	 renal	 survival,	
and	all‐cause	mortality,	we	assessed	only	all‐cause	mortality	in	this	
study.	For,	in	our	retrospective	AAV	cohort,	the	clinical	significance	
of	BVAS	at	diagnosis	exhibited	the	difference	patterns	according	to	
AAV	 variants:	 BVAS	was	 associated	with	 relapse	 of	MPA	 and	 re‐
fractory	disease	of	GPA,	but	not	with	the	prognosis	of	EGPA.	In	this	
study,	BVAS	at	diagnosis	≥16	could	not	predict	all‐cause	mortality	
in	 patients	with	AAV.	Whereas,	 patients	with	 FFS	 (2009)	 at	 diag‐
nosis	 ≥2	 exhibited	 the	 higher	 all‐cause	mortality	 rate	 than	 those	
without	during	 follow‐up	 (P	=	 .001),	which	 is	 compatible	with	our	
previous study.17‐19	On	the	other	hand,	MVIA	at	diagnosis	≥1.35	was	
significantly	associated	with	all‐cause	mortality.	 In	fact,	the	cutoff	
of	MVIA	at	diagnosis	was	derived	from	severe	AAV	based	on	BVAS	
at	diagnosis	≥16	but	not	based	on	all‐cause	mortality.	Nevertheless,	
MVIA	at	diagnosis	≥1.35	 indeed	predicted	all‐cause	mortality.	We	
assumed	that	during	follow‐up,	the	effects	of	each	of	BVAS	items	
and	MVIA	variables	on	all‐cause	mortality	might	have	been	differ‐
ent.	 It	 is	 assumed	 that	 the	 variables	 of	MVIA	may	 have	 been	 es‐
sential	parameters	for	predicting	all‐cause	mortality	compared	with	
all	 items	of	BVAS.	As	a	result,	MVIA	at	diagnosis	could	assess	the	
cross‐sectional	activity	and	predict	all‐cause	mortality	better	than	
BVAS	at	diagnosis.
We	 also	 focused	 on	 FFS	 at	 diagnosis	 ≥2,	 developed	 another	
new	equation	of	MVIA	based	on	FFS	at	diagnosis	and	the	predictive	
value	 for	 all‐cause	mortality	between	MVIA	based	on	BVAS	and	
that	based	on	FFS	at	diagnosis.	We	obtained	the	optimal	cutoffs	of	
laboratory	variables	at	diagnosis	for	FFS	at	diagnosis	≥2.	The	opti‐
mal	cutoffs	of	variables	are	as	below:	neutrophil	count	≥	7570.0/
mm3;	 lymphocyte	 count	 ≤	 1475.0/mm3;	 hemoglobin	 ≤	 10.8	 g/
dL;	 creatinine	 ≥	 1.16	 mg/dL;	 serum	 albumin	 ≤	 3.65	 g/dL;	 and	
CRP	 ≥39.35	 mg/L	 (Table	 S2).	 In	 the	 univariable	 logistic	 regres‐
sion	analysis,	significant	ORs	for	FFS	at	diagnosis	≥2	were	found	
in all variables with the significant cutoffs. In the multivariable 
logistic	 regression	 analysis,	 neutrophil	 ≥	 7570.0/mm3,	 hemoglo‐
bin	≤	10.8	g/dL,	and	creatinine	≥	1.16	mg/dL	were	significantly	as‐
sociated	with	FFS	at	diagnosis	≥2	(Table	S3).	We	assigned	a	weight	
to each variable according to the slopes and expressed another 
new	MVIA	based	on	FFS	at	diagnosis	=	1.2	×	(Neutrophil	≥	7570.0/
mm3:	yes	=	1	or	no	=	0)	+	1.6	×	(Hemoglobin	≤	10.8	g/dL:	yes	=	1	
or	no	=	0)	+	1.9	×	(Creatinine	≥	1.16	mg/dL:	yes	=	1	or	no	=	0).	In	
addition,	we	obtained	 the	 optimal	 cutoff	 of	MVIA	 for	 FFS	 at	 di‐
agnosis	≥2	as	1.75	 (sensitivity	0.667	and	 specificity	0.689)	using	
the	AUROC	 curve	 (area	 0.850;	 Figure	 S2).	We	 found	 that	MVIA	
based	 on	 FFS	 at	 diagnosis	 ≥1.75	 exhibited	 no	 significant	 differ‐
ence	 in	patient	survival	rate	from	MVIA	based	on	FFS	at	diagno‐
sis	<1.75	(P	=	.072;	Figure	S3).	Therefore,	we	conclude	that	MVIA	
based	on	BVAS	at	diagnosis	≥1.35	could	predict	all‐cause	mortality	
during	follow‐up	in	patients	with	AAV	than	MVIA	based	on	FFS	at	
diagnosis	≥1.75.
Our study has several limitations. This study is based on study 
population that was not large enough to represent the clinical data 
of	 all‐Korean	 patients	 with	 AAV.	 Also,	 due	 to	 the	 retrospective	
study	design,	the	usefulness	of	MVIA	was	not	explored	for	assess‐
ing	the	serially	changing	the	cross‐sectional	activity	and	severity	
of	 AAV	 under	 the	 administration	 of	 immunosuppressive	 drugs.	
However,	 we	 hope	 that	 future	 nationwide	 prospective	 studies	
with	a	larger	number	of	patients	with	AAV	could	overcome	all	of	
these issues.
Our	study	has	several	merits.	We	have	first	developed	an	AAV‐
specific	index	for	assessing	the	cross‐sectional	activity	and	severity	
and	predicting	all‐cause	mortality	in	patients	with	AAV.	Because	we	
included	patients,	who	had	been	classified	as	AAV	at	the	same	de‐
partment	of	one	tertiary	hospital,	our	study	was	able	to	minimize	the	
inter‐centric	variation.	Also,	our	 institute	 is	one	of	 the	biggest	 ter‐
tiary	university	hospitals	in	Korea,	and	furthermore,	our	AAV	cohort	
is	the	only	one	in	Korea.	So,	almost	all	the	patients	are	transferred	
to	our	 institute	when	a	situation	occurs	 requiring	consideration	of	
death	in	patients	with	AAV.	In	addition,	we	tried	to	contact	patients	
with	AAV,	who	were	not	followed	up,	by	phone	and	so	we	could	pre‐
cisely	confirm	all‐cause	mortality,	although	the	causes	of	death	were	
not	known	in	all	patients.	Lastly,	given	that	the	clinical	features	and	
the	prognosis	of	AAV	may	vary	based	on	geographical	 and	ethnic	
differences,	this	study	first	demonstrated	the	clinical	implication	of	
MVIA	in	Korean	patients	with	AAV.
5  | CONCLUSION
A	new	AAV‐specific	MVIA	could	assess	the	cross‐sectional	activity	
and	severity	and	predict	all‐cause	mortality	 in	 immunosuppressive	
drug‐naïve	patients	with	AAV	during	follow‐up.
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